Introduction
Uloric (Febuxostat) is a drug commonly prescribed for the management of chronic hyperuricemia in adults with gout. Takeda Pharmaceuticals, the manufacturer of Uloric, may have failed to warn users of this medication of the increased risk of heart attacks and strokes, resulting in a Uloric lawsuit.
History of the Case
Our Uloric lawsuit attorneys are currently investigating potential claims for those who have experienced the following injuries after using the drug Uloric:
- Heart Attack
- Heart-related Death
- Deep-vein Thrombosis
- Angioplasty
Injuries Related to Product
Gout is a form of arthritis, commonly occurring in the feet and toes, which results from elevated uric acid levels in the bloodstream. This elevated level of uric acid in the body can lead to sudden, severe attacks of pain, swelling, and tenderness in the joints.
Uloric blocks the metabolic processes in the body that create uric acid, therefore relieving pain and inflammation in the joints. If you’ve experienced this issue, you may have a place in our Uloric lawsuit.
Additional Literature
Deadly Findings of Uloric
Uloric is manufactured by Takeda Pharmaceuticals and hit the market as soon as it gained FDA approval in February 2009. After approval, the FDA required Takeda to conduct a post-market safety clinical trial due to unanswered questions and continued cardiovascular concerns.
The preliminary results of the 6,000-patient study were published on March 2018 in The New England Journal of Medicine. The results concluded Uloric posed a significantly increased risk of cardiovascular-related death, heart attacks, and strokes compared to users of allopurinol. If you or a loved one has experienced one of these problems, you we can represent you in the Uloric lawsuit… Continued
FDA Updated Safety Notices
Updated Safety Notice released in November 2017:
Updated Safety Notice released in Feburary 2019:
The FDA issues another updated safety notice which included a black box warning regarding the increased risk for heart attacks and death.
